Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sperogenix Files for Approval of Duchenne Muscular Dystrophy Therapy in China

publication date: Mar 28, 2024

Sperogenix Therapeutics of Shanghai announced its NDA for Agamree (vamorolone), a treatment for Duchenne muscular dystrophy (DMD), has been accepted for review by China’s Center for Drug Evaluation (CDE). Two years ago, Sperogenix in-licensed greater China rights to the drug from Santhera Therapeutics of Switzerland in a $124 million agreement. A novel drug, Agamree binds to the same receptor as glucocorticoids but modifies its downstream activity for better safety. Sperogenix is a China rare disease company. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here